Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Other Operating Expenses for 4 consecutive years, with -$11.4 million as the latest value for Q2 2024.

  • Quarterly Other Operating Expenses fell 428.53% to -$11.4 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was -$11.4 million through Mar 2025, down 56.86% year-over-year, with the annual reading at -$13.2 million for FY2024, 105.64% down from the prior year.
  • Other Operating Expenses for Q2 2024 was -$11.4 million at Relay Therapeutics, down from -$1.8 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $134.9 million in Q2 2021, with the low at -$11.4 million in Q2 2024.
  • Average Other Operating Expenses over 4 years is $8.2 million, with a median of -$1.2 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses plummeted 1361.24% in 2022, then surged 80.4% in 2023.
  • Over 4 years, Other Operating Expenses stood at $836000.0 in 2021, then tumbled by 1361.24% to -$10.5 million in 2022, then soared by 80.4% to -$2.1 million in 2023, then crashed by 450.27% to -$11.4 million in 2024.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$11.4 million, -$1.8 million, and -$2.1 million for Q2 2024, Q1 2024, and Q4 2023 respectively.